Kneat.com (KSI) investor relations material

Business and product updates

• Reported strong revenue growth, with annual recurring revenue rising from CAD 15 million to CAD 74 million over four years.

• Added new strategic customers, including two in early 2026, and now serves eight of the top 10 global life sciences companies.

• Recognized as the leader in pharma and biotech software for the third consecutive year by user ratings.

• Platform is positioned as a compliance workflow productivity tool, focusing on data integrity and audit trails.

• Primary revenue model is SaaS subscriptions, with ARR as the key metric and some supporting services.

Technology and innovation

• Introduced AI features such as content review assistant, NLP, user support chatbot, and instant language translation.

• AI roadmap includes deeper automation in lifecycle documentation, risk management, and process optimization.

• AI is used to enhance both the platform and internal business operations.

• Emphasizes the need for deterministic, traceable, and audit-ready processes in regulated environments.

Financial performance and growth strategy

• Net recurring revenue rate of 115% reflects strong customer expansion.

• Land-and-expand model drives growth, with new customers starting small and scaling to multi-million ARR over time.

• Path to profitability targeted for 2026, with limited additional expense expected.

• Sales cycles have matured, with increased competition but high win rates (over 80% of RFPs in the past year).